SAN DIEGO, Feb. 3, 2015 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage
biopharmaceutical company, today announced that the Company's Chief
Executive Officer, Brian M. Culley,
will present at the 17th Annual BIO CEO & Investor Conference on
Monday, February 9, 2015 at
3:30 p.m. Eastern time in the Park
South Salon at the Waldorf Astoria hotel in New York.
Interested parties can access a live audio webcast and slide
presentation on the Mast Therapeutics web site at
www.masttherapeutics.com. An archived presentation will be
available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The
Company is leveraging the MAST (Molecular Adhesion and Sealant
Technology) platform, derived from over two decades of clinical,
nonclinical and manufacturing experience with purified and
non-purified poloxamers, to develop vepoloxamer (MST-188), its lead
product candidate, for serious or life-threatening diseases and
conditions typically characterized by impaired microvascular blood
flow and damaged cell membranes.
The Company is enrolling subjects in EPIC, a pivotal Phase 3
study of vepoloxamer in sickle cell disease, and in a Phase 2 study
to evaluate whether vepoloxamer improves the effectiveness of
recombinant tissue plasminogen activator therapy in patients with
acute limb ischemia. The Company also is planning to initiate
a Phase 2 study of vepoloxamer in patients with acute decompensated
heart failure in the second quarter of 2015. More information can
be found on the Company's web site at www.masttherapeutics.com.
(Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements include, but are not limited to,
statements relating to anticipated milestones for the Company's
development programs. Among the factors that could cause or
contribute to material differences between the Company's actual
results and the expectations indicated by the forward-looking
statements are risks and uncertainties that include, but are not
limited to: delays in the commencement or completion of clinical
studies, including as a result of difficulties in obtaining
regulatory agency agreement on clinical development plans or
clinical study design, opening trial sites, enrolling study
subjects, manufacturing sufficient quantities of clinical trial
material, being subject to a "clinical hold," and/or suspension or
termination of a clinical study, including due to patient safety
concerns or lack of funding; the uncertainty of outcomes in ongoing
and future studies of the Company's product candidates and the risk
that its product candidates, including vepoloxamer, may not
demonstrate adequate safety, efficacy or tolerability in one or
more such studies; the potential for institutional review boards or
the FDA or other regulatory agencies to require additional
nonclinical or clinical studies prior to initiation of a planned
clinical study of a product candidate; the risk that, even if
clinical studies are successful, the FDA or other regulatory
agencies may determine they are not sufficient to support a new
drug application; the potential that, even if clinical studies of a
product candidate in one indication are successful, clinical
studies in another indication may not be successful; the Company's
reliance on contract research organizations (CROs), contract
manufacturing organizations (CMOs), and other third parties to
assist in the conduct of important aspects of development of its
product candidates, including clinical studies, manufacturing, and
regulatory activities for its product candidates, and that such
third parties may fail to perform as expected; the Company's
ability to obtain additional funding as needed on a timely basis or
on acceptable terms, or at all; the potential for the Company to
delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner its product
candidates at inopportune times or pursue less expensive but
higher-risk and/or lower return development paths if it is unable
to raise sufficient additional capital as needed; the risk that,
even if the Company successfully develops a product candidate in
one or more indications, it may not realize commercial success with
its products and may never generate revenue sufficient to achieve
profitability; the risk that the Company is not able to adequately
protect its intellectual property rights relating to the MAST
platform and vepoloxamer or AIR001 and prevent competitors from
duplicating or developing equivalent versions of its product
candidates; and other risks and uncertainties more fully described
in the Company's press releases and periodic filings with the
Securities and Exchange Commission. The Company's public filings
with the Securities and Exchange Commission are available at
www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-17th-annual-bio-ceo--investor-conference-on-february-9th-300029592.html
SOURCE Mast Therapeutics, Inc.